This was demonstrated in the current trial where the provision of education and written material resulted in a large proportion of the surveyed patients contacting, or intending to contact, their prescriber to discuss the possibility of reducing their PPI therapy

This was demonstrated in the current trial where the provision of education and written material resulted in a large proportion of the surveyed patients contacting, or intending to contact, their prescriber to discuss the possibility of reducing their PPI therapy. In conclusion, an electronic quick into community pharmacy-dispensing software was successfully utilized to encourage quality use of PPIs. ABBV-4083 (0.65) per control pharmacy. Summary The use of electronic decision support prompts in community pharmacy practice can promote the quality use of medicines. 0.001). Table 1 Intervention rates across the trial organizations thead th rowspan=”1″ colspan=”1″ /th th align=”remaining” ABBV-4083 colspan=”2″ rowspan=”1″ PPI quick /th th align=”remaining” colspan=”2″ rowspan=”1″ Control /th th rowspan=”1″ colspan=”1″ /th th align=”remaining” rowspan=”1″ colspan=”1″ Esomeprazole 40 mg /th th align=”remaining” rowspan=”1″ colspan=”1″ Pantoprazole 40 mg /th th align=”remaining” rowspan=”1″ colspan=”1″ Esomeprazole 40 mg /th th align=”remaining” rowspan=”1″ colspan=”1″ Pantoprazole 40 mg /th /thead Quantity of PPI step-down interventions1581243216Number of prescriptions7967895712 58414 883Intervention rate/100 prescriptions1.981.380.250.11Intervention rate/100 prescriptions1.670.17 Open in a separate window PPI, proton pump inhibitor. Examination of prescription data for each step-down treatment that occurred within the 1st 28 days of the trial recognized 34 individuals with PPI therapy reduction, 28 of whom were in the PPI quick group. Twenty-seven individuals resulted in dose reduction of the targeted medications from 40 mg to 20 mg, and in one patient the reduction was from esomeprazole 40 mg twice daily to once daily. In six individuals medications were changed to another PPI (all of which were less expensive). In one patient therapy was changed to a less expensive histamine H2-receptor antagonist. The average 1-month cost saving per PPI quick pharmacy was found to be AUD 7.98 (4.95). The average 1-month cost saving per control arm pharmacy was found to be AUD 1.05 (0.65). The effect of the quick was most prominent in the 1st 2 months of the trial (Number 1) and is mimicked in the costing. A cost estimation applying the cost-saving effect of the quick in each of weeks 1 and 2 of AUD 7.98 and allowing this to accumulate ABBV-4083 for 10 further weeks resulted in a 1-12 months saving of AUD 183.60 (114) per pharmacy. When extrapolated to all 5006 Australian pharmacies [18], and subtracting the control group cost saving, the cost saving attributable to the quick would be nearly AUD 800 000 (497 000) in the 1st year, and would be expected to increase in subsequent years because of the accumulating cost-saving effect. Seventy-six responses were received from 252 PPI treatment surveys sent to individuals from PPI quick pharmacies. Forty-eight individuals (63%) had examined their medication therapy in discussion with their GP and a further 19 (25%) intended to do so. Of the individuals who experienced consulted their GP, 31 of these consultations resulted in a change of therapy C 20 dose reductions, six cessations of therapy, three dose raises and one change from esomeprazole to pantoprazole (unfamiliar strength). One response was unclear. Conversation The overprescribing of high-dose PPIs is an issue ABBV-4083 that has been highlighted to Australian doctors and pharmacists [10, 11]. The PPI quick offered the opportunity for pharmacists to perform short patient-focused interventions related to PPI therapy reduction. Rabbit Polyclonal to FRS3 The recording of PPI dose reduction interventions declined in the prompted group on the duration of the trial. Several factors may have contributed to this decrease. First, individuals with chronic conditions typically attend their local pharmacy regular monthly. Therefore, most individuals suitable for therapy reduction were likely to have been identified within the first month of the trial. Second, the quick was not highly specific, and was triggered for individuals who were not suitable for therapy reduction, or who had not had therapy reduced following a earlier intervention. These factors may have caused fatigue, as has been identified in additional decision support tests [19C22]. The extrapolation of cost savings for 1 year of therapy if this quick was implemented for only 2 months in all Australian pharmacies was found to be nearly AUD 800 000 (497 000). The economic benefits of the therapy reduction quick are likely to be understated as follow-up prescription data were limited to prescriptions dispensed in the trial pharmacy only, and prescription materials may have lasted beyond the follow-up period. Patients.